[1]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:The major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.
|
[2]WU J, YANG S, XU K, et al.Patterns and trends of liver cancer incidence rates in eastern and southeastern Asian countries (1983-2007) and predictions to 2030[J].Gastroenterology, 2018, 154 (6) :1719-1728.
|
[3]FORNER A, GILABERT M, BRUIX J, et al.Treatment of intermediate-stage hepatocellular carcinoma[J].Nat Rev Clin Oncol, 2014, 11 (9) :525-535.
|
[4]BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:An update[J].Hepatology, 2011, 53 (3) :1020-1022.
|
[5]VAUTHEY JN, LAUWERS GY, ESNAOLA NF, et al.Simplified staging for hepatocellular carcinoma[J].J Clin Oncol, 2002, 20 (6) :1527-1536.
|
[6]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
|
[7]BENSON AB 3rd, D'ANGELICA MI, ABBOTT DE, et al.NCCN guidelines insights:Hepatobiliary cancers, version 1.2017[J].J Natl Compr Canc Netw, 2017, 15 (5) :563-573.
|
[8]MARRERO JA, AHN J, RAJENDER REDDY K, et al.ACG clinical guideline:The diagnosis and management of focal liver lesions[J].Am J Gastroenterol, 2014, 109 (9) :1328-1347.
|
[9] HEIMBACH JK, KULIK LM, FINN RS, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J].Hepatology, 2018, 67 (1) :358-380.
|
[10]European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:Management of hepatocellular carcinoma[J].J Hepatol, 2012, 56 (4) :908-943.
|
[11]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
|
[12]AMIN MB.AJCC cancer staging manual (8th edition) [M].Chicago:Springer, 2017:185-202.
|
[13]FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2018, 391 (10127) :1301-1314.
|
[14]KOH WJ, ABU-RUSTUM NR, BEAN S, et al.Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw, 2018, 16 (2) :170-199.
|
[15]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of hepatocellular carcinoma[J].J Hepatol, 2018.[Epub ahead of print]
|
[16]MAZZAFERRO V, REGALIA E, DOCI R, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J].N Engl J Med, 1996, 334 (11) :693-699.
|
[17]YAO FY, FERRELL L, BASS NM, et al.Liver transplantation for hepatocellular carcinoma:Expansion of the tumor size limits does not adversely impact survival[J].Hepatology, 2001, 33 (6) :1394-1403.
|
[18]FAN J, YANG GS, FU ZR, et al.Liver transplantation outcomes in1, 078 hepatocellular carcinoma patients:A multi-center experience in Shanghai, China[J].J Cancer Res Clin Oncol, 2009, 135 (10) :1403-1412.
|
[19]LI J, YAN LN, YANG J, et al.Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients[J].World J Gastroenterol, 2009, 15 (33) :4170-4176.
|
[20]ZHENG SS, XU X, WU J, et al.Liver transplantation for hepatocellular carcinoma:Hangzhou experiences[J].Transplantation, 2008, 85 (12) :1726-1732.
|
[21]IASONOS A, SCHRAG D, RAJ GV, et al.How to build and interpret a nomogram for cancer prognosis[J].J Clin Oncol, 2008, 26 (8) :1364-1370.
|
[22]KARAKIEWICZ PI, BRIGANTI A, CHUN FK, et al.Multi-institutional validation of a new renal cancer-specific survival nomogram[J].J Clin Oncol, 2007, 25 (11) :1316-1322.
|
[23]van ZEE KJ, MANASSEH DM, BEVILACQUA JL, et al.A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy[J].Ann Surg Oncol, 2003, 10 (10) :1140-1151.
|
[24]STERNBERG CN.Are nomograms better than currently available stage groupings for bladder cancer?[J].J Clin Oncol, 2006, 24 (24) :3819-3820.
|
[25]LI J, ZHOU J, YANG PH, et al.Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma[J].Eur J Cancer, 2016, 62:86-95.
|
[26]LI Y, XIA Y, LI J, et al.Prognostic nomograms for pre-and postoperative predictions of long-term survival for patients who underwent liver resection for huge hepatocellular carcinoma[J].J Am Coll Surg, 2015, 221 (5) :962-974.
|
[27]YANG P, QIU J, LI J, et al.Nomograms for pre-and postoperative prediction of long-term survival for patients who underwent hepatectomy for multiple hepatocellular carcinomas[J].Ann Surg, 2016, 263 (4) :778-786.
|
[28]ZOU Q, LI J, WU D, et al.Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma[J].Ann Surg Oncol, 2016, 23 (8) :2618-2626.
|
[29]LI J, LIU Y, YAN Z, et al.A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy[J].Br J Cancer, 2014, 110 (5) :1110-1117.
|
[30]QIAO G, LI J, HUANG A, et al.Artificial neural networking model for the prediction of post-hepatectomy survival of patients with early hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2014, 29 (12) :2014-2020.
|
[31]DU M, CHEN L, ZHAO J, et al.Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma[J].BMC Cancer, 2014, 14:38.
|
[32]RODRIGUEZ-PERALVAREZ M, LUONG TV, ANDREANA L, et al.A systematic review of microvascular invasion in hepatocellular carcinoma:Diagnostic and prognostic variability[J].Ann Surg Oncol, 2013, 20 (1) :325-339.
|
[33]ZHOU YM, YANG JM, LI B, et al.Risk factors for early recurrence of small hepatocellular carcinoma after curative resection[J].Hepatobiliary Pancreat Dis Int, 2010, 9 (1) :33-37.
|
[34]ESNAOLA NF, LAUWERS GY, MIRZA NQ, et al.Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation[J].J Gastrointest Surg, 2002, 6 (2) :224-232.
|
[35]Mc HUGH PP, GILBERT J, VERA S, et al.Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma[J].HPB (Oxford) , 2010, 12 (1) :56-61.
|
[36]HOU Y, ZOU Q, GE R, et al.The critical role of CD133 (+) CD44 (+/high) tumor cells in hematogenous metastasis of liver cancers[J].Cell Res, 2012, 22 (1) :259-272.
|
[37]WANG K, LIU J, YAN ZL, et al.Overexpression of aspartyl- (asparaginyl) -beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome[J].Hepatology, 2010, 52 (1) :164-173.
|
[38]CUCCHETTI A, PISCAGLIA F, GRIGIONI AD, et al.Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network:A pilot study[J].J Hepatol, 2010, 52 (6) :880-888.
|
[39]LEI Z, LI J, WU D, et al.Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria[J].JAMA Surg, 2016, 151 (4) :356-363.
|
[40]HUANG A, ZHAO X, YANG XR, et al.Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma[J].J Hepatol, 2017, 67 (2) :293-301.
|
[41]XIA Y, QIU Y, LI J, et al.Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection:A randomized controlled trial[J].Ann Surg Oncol, 2010, 17 (12) :3137-3144.
|